| Market Cap | 1.34B 1.2B 1.1B 999M 1.87B 127B 1.9B 13.14B 5.28B 66.81B 5.02B 4.91B 211B | P/E 2026 * |
-4.85x | P/E 2027 * | -3.73x |
|---|---|---|---|---|---|
| Enterprise Value | 729M 653M 601M 544M 1.02B 69.26B 1.04B 7.17B 2.88B 36.43B 2.74B 2.68B 115B | EV / Sales 2026 * |
17.4x | EV / Sales 2027 * | 17.3x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 31/12/2006 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 14/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 30/06/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 31/07/2000 |
Robert Chess
CHM | Chairman | 69 | 30/04/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 31/01/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.34B | |
| -0.62% | +0.50% | +33.92% | +60.07% | 64.38B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.16B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.16B | |
| -2.91% | -4.42% | +23.35% | +50.72% | 45.33B | |
| -0.32% | -1.73% | +20.40% | +98.86% | 42.25B | |
| +0.53% | +2.70% | +226.22% | +946.57% | 40.78B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 33.8B | |
| +1.22% | -1.39% | +13.92% | +46.95% | 32.25B | |
| -1.29% | -1.72% | +21.00% | -6.85% | 23.57B | |
| Average | +0.05% | +4.72% | +53.53% | +164.90% | 43.63B | |
| Weighted average by Cap. | +0.05% | +3.64% | +50.30% | +163.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.82M 37.46M 34.45M 31.22M 58.35M 3.97B 59.45M 411M 165M 2.09B 157M 154M 6.59B | 53.42M 47.84M 44.01M 39.87M 74.53M 5.07B 75.93M 525M 211M 2.67B 200M 196M 8.41B |
| Net income | -246M -221M -203M -184M -344M -23.4B -350M -2.42B -972M -12.31B -925M -905M -38.81B | -363M -325M -299M -271M -506M -34.43B -515M -3.56B -1.43B -18.11B -1.36B -1.33B -57.12B |
| Net Debt | -608M -545M -501M -454M -849M -57.76B -865M -5.98B -2.4B -30.38B -2.28B -2.23B -95.82B | -415M -372M -342M -310M -579M -39.43B -590M -4.08B -1.64B -20.74B -1.56B -1.53B -65.41B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
